Alvar Agustí 1 , 2 , * , Lisa D. Edwards 3 , Stephen I. Rennard 4 , William MacNee 5 , Ruth Tal-Singer 6 , Bruce E. Miller 6 , Jørgen Vestbo 7 , 8 , David A. Lomas 9 , Peter M. A. Calverley 10 , Emiel Wouters 11 , Courtney Crim 3 , Julie C. Yates 3 , Edwin K. Silverman 12 , Harvey O. Coxson 13 , Per Bakke 14 , Ruth J. Mayer 3 , Bartolome Celli 12 , for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators
18 May 2012
Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552).
Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p<0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p<0.001) compared to non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by the majority of previous studies and are often and easily measured in clinical practice.